Prostate — In Follow-up
Prostate cancer is the most commonly diagnosed cancer in Australian people. If detected early, when disease has not spread there is a high chance of cure. Relapse, however, is not uncommon despite careful selection of patients prior to surgery or radiotherapy. This, in part, reflects a failure to detect disease spread at baseline due to limited accuracy of current scanning techniques. More accurate scanning may improve outcomes by redirecting patients with disease spread from futile local treatments to more appropriate management. This clinical trial will investigate a new type of scan which provides whole body images of prostate cancer spread. Early experience suggests that this new technology, called PSMA PET/CT (prostate specific membrane antigen positron emission tomography/computed tomography), is superior to current scanning techniques. PSMA PET/CT has capacity for wide availability at relatively low cost. Performing a single better test rather than several less accurate scans will also be cheaper, improve patient experience and expose patients to lower amounts of radiation. This is a randomised study at multiple centres around Australia comparing PSMA-PET/CT to conventional imaging. If the initial work-up does not demonstrate tumour spread, patients will cross-over to the other imaging arm. We hope to prove that PSMA-PET/CT has superior diagnostic performance, should be used as a first-line test for staging prior to surgery or radiotherapy and will result in significant changes to patient management. Results of this trial will be used to support funding of this new technology in Australia and internationally.
If you think this trial might be right for you, please ask your doctor.
A prospective randomised multi-centre study of the impact of Ga-68 PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy
Professor Michael Hofman
1. Untreated biopsy-proven prostate cancer being considered for curative intent treatment with surgery or radiotherapy 2. High risk, defined by: PSA≥20ng/mL or Gleason grade group 3-5 or clinical stage≥T3
Funding from Prostate Cancer Foundation of Australia (PCFA) through a Clinical Trials Grant from Movember. Sponsor is the Peter MacCallum Cancer Centre.
Calvary Mater Newcastle
Royal North Shore Hospital - Northern Sydney Local Health District
Peter MacCallum Cancer Centre
Monash Medical Centre - Clayton campus
St Vincent's Hospital - Melbourne
Royal Brisbane & Women's Hospital
Princess Alexandra Hospital
Royal Adelaide Hospital - Central Adelaide Local Health Network Inc.
South Australian Health and Medical Research Institute
Sir Charles Gairdner Hospital